Efficacy and nephrotoxicity associated with various colistin dosing schemas for the treatment of multidrug resistant (MDR) infections: Infectious Diseases: Vol 50, No 6

152

Views

CrossRef citations to date

Altmetric

Click to increase image sizeClick to decrease image size

Disclosure statement

Research grants from Merck Co, Allergan and Cubist; Member of the Speaker Bureau for the Medicines Company.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Efficacy and nephrotoxicity associated with various colistin dosing schemas for the treatment of multidrug resistant (MDR) infections

Information for

Open access

Opportunities

Help and information

Efficacy and nephrotoxicity associated with various colistin dosing schemas for the treatment of multidrug resistant (MDR) infections

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature